Clinical trials: Stage IV Melanoma
Metastatic Melanoma
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation
This open-label phase II trial studies how well olaparib in combination with pembrolizumab works in treating patients with advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation / alteration.
- Trial name
- NCT04633902
- Testing
- Olaparib, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- California Pacific Medical Center Research Institute
Stage III Melanoma, Stage IV Melanoma
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma
This randomized phase II trial is studying how well cilengitide works in treating patients with unresectable stage III or stage IV melanoma. Cilengitide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00082875
- Testing
- cilengitide, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma (Skin), Metastatic Melanoma
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
In this first-in human, phase I/IIa study, the safety and efficacy of [212Pb]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in…
- Conditions
- Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
- Trial name
- NCT05655312
- Testing
- [203Pb]VMT01, [212Pb]VMT01, Nivolumab
- Where
- 16 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Metastatic Melanoma
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
The purpose of this study is to treat metastatic melanoma with a combination of standard chemotherapy (decitabine and Temozolomide in a dose escalation scheme) with an study drug called panobinostat.
- Trial name
- NCT00925132
- Testing
- Temozolomide, Decitabine, Panobinostat
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Iowa
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
This randomized pilot clinical trial studies vaccine therapy and sargramostim in treating patients with stage IV malignant melanoma.
- Trial name
- NCT00006243
- Testing
- tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma (Skin)
Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying immunization using two different gp100 protein vaccines to compare how well they work in…
- Trial name
- NCT00072085
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
BRAFV600 Mutation, Stage IV Melanoma
Radiation Use During Vemurafenib Treatment
Patients are being asked to take part because they have melanoma that has spread to other organs in their body (metastatic). As part of this study, patients will receive radiation therapy and an approved drug (Vemurafenib).
- Trial name
- NCT01843738
- Testing
- Radiation therapy, Vemurafenib
- Where
- United States
- Sponsor
- University of Utah
Metastatic Cancer, Melanoma
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Background: One possible treatment for advanced melanoma involves collecting white blood cells from the person with cancer and growing them in a laboratory. The cells can then be given back to the donor.
- Trial name
- NCT01585415
- Testing
- Vemurafenib, Young TIL, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Advanced Metastatic Melanoma
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
- Trial name
- NCT03957551
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- John Rieth
Malignant Melanoma
A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma
To evaluate the efficacy of vemurafenib in combination with cobimetinib (GDC-0973), compared with vemurafenib and placebo, in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or…
- Trial name
- coBRIM (NCT01689519)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 495 people
- Sponsor
- Hoffmann-La Roche
Melanoma
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when…
- Trial name
- NCT06190951
- Testing
- cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab
- Where
- 104 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Melanoma
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma
To determine the safety and efficacy of the combination of HDI and anti-CTLA-4 monoclonal antibody for patients with recurrent inoperable stage III or stage IV melanoma.
- Trial name
- NCT00610857
- Testing
- Anti-CTLA4 monoclonal antibody and HDI
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Ahmad Tarhini
GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
The purpose of this study is to determine whether GSK1120212, a MEK inhibitor, is an effective and safe treatment for cancer subjects with metastatic uveal melanoma and mutation-positive GNAQ or GNA11 metastatic melanoma.
- Conditions
- GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma, Cancer, Metastatic Uveal Melanoma
- Trial name
- NCT01328106
- Testing
- GSK1120212
- Sponsor
- GlaxoSmithKline
Malignant Melanoma
Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
The purpose of this study is to provide treatment with nivolumab in combination with ipilimumab to subjects who are anti-(CTLA)-4 and anti-PD-1 treatment-naive and have unresectable or metastatic melanoma.
- Trial name
- CheckMate218 (NCT02186249)
- Testing
- Nivolumab, Ipilimumab
- Where
- 66 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
This is a single center, single arm phase I trial to test the feasibility and safety of Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) followed by nivolumab rescue in unresectable locally advanced or metastatic…
- Trial name
- NCT03475134
- Testing
- TIL, Cyclophosphamide, Fludarabine
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Stage IV Melanoma
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
The purpose of this study is to determine if LC beads loaded with Doxorubicin are a safe and effective treatment for melanoma that has spread to the liver.
- Trial name
- DEBDOX (NCT01010984)
- Testing
- LC beads loaded with Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Robert C. Martin
Metastatic or Unresectable Melanoma
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination treatment for unresectable or metastatic…
- Trial name
- NCT04187833
- Testing
- Nivolumab, Talazoparib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Sodium stibogluconate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Interferon may interfere with the growth of cancer cells.
- Trial name
- NCT00311558
- Testing
- recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- The Cleveland Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.